SAN FRANCISCO, April 3, 2026 /PRNewswire/ — ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which ...

Immunotherapy and targeted therapy are often the first lines of treatment for advanced kidney cancer, with surgery and ...

New research identifies distinct urinary metabolites linked to bladder cancer and recurrence, raising hope for non-invasive ...

Dr Thomas Flaig from the University of Colorado Anschutz discusses a paradigm shift in treating urothelial carcinoma patients ...

Ovarian cancer remains the deadliest gynecologic cancer, largely because it is rarely found early. Symptoms are often vague, ...

New urinary biomarkers show promise for bladder cancer detection and recurrence prediction. Learn more about this non-invasive diagnostic approach.

The Centers for Medicare & Medicaid Services has issued a permanent billing and reimbursement J-code, J9183, for the ...

Two years ago, the Emerald-1 trial hit its primary endpoint, showing that a cocktail of Imfinzi, Avastin and TACE reduced the ...

Positive high-level results from the EMERALD-3 Phase III trial showed AstraZeneca's Imfinzi (durvalumab) in combination with Imjudo (tremelimumab ...

Fortis Hospital, Bannerghatta Road, received the Service Excellence in Robotic Urological Surgery & Kidney Transplant award, highlighting their commitment to innovation and precision. Dr. Mohan ...

For people diagnosed with actual early stage breast cancer, there would be an end date to their drug therapy too. Maybe a year of Herceptin (trastuzumab), maybe five years of anti-estrogen, something, ...

The U.S. Food and Drug Administration (USFDA) has issued a warning to ImmunityBio, stating that its promotional materials for ...